ARTICLE
26 July 2021

End Of Health Crisis Will Put Heaps Of Covid Products In Limbo

MF
Morrison & Foerster LLP

Contributor

Known for providing cutting-edge legal advice on matters that are redefining industries, Morrison & Foerster has 17 offices located in the United States, Asia, and Europe. Our clients include Fortune 100 companies, leading tech and life sciences companies, and some of the largest financial institutions. We also represent investment funds and startups.
Stacy Cline Amin, former Chief Counsel of the Food and Drug Administration, spoke with Bloomberg Law about how FDA might transition more than 400 products from emergency ...
United States Food, Drugs, Healthcare, Life Sciences

Stacy Cline Amin, former Chief Counsel of the Food and Drug Administration, spoke with Bloomberg Law about how FDA might transition more than 400 products from emergency use status to approved status, if the public health emergency with COVID-19 ends.

"The sheer volume of authorized products could be potentially very disruptive, if not transitioned well by FDA," said Stacy. "FDA is aware of that and thinking about it."

The emergency also may not go away anytime soon, with the emergence of new variants and as the pandemic continues to rage globally, Amin noted.

"It may not be the case that the public health emergency for us is really, you know, coming to a quick close," she said.

Read the full article  (subscription required).

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More